| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.09 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.056 | 0.09 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.09 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.074 | 0.09 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.1 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |